Mark Storey (@protonstorey) 's Twitter Profile
Mark Storey

@protonstorey

Dr. Mark Storey MD - Radiation Oncologist. @OKProtonCenter. Background: #MDAnderson @VanderbiltU @BMESociety #RadOnc
My blog: protons101.com

ID: 1140445969131167744

linkhttp://www.protons101.com calendar_today17-06-2019 02:28:02

3,3K Tweet

1,1K Followers

432 Following

Mark Storey (@protonstorey) 's Twitter Profile Photo

When you review ref 14 and 15 - you realize they have 18 and 20 patients respectively. If at that point, you don't question the strength of the rec....

When you review ref 14 and 15 - you realize they have 18 and 20 patients respectively.  If at that point, you don't question the strength of the rec....
Mark Storey (@protonstorey) 's Twitter Profile Photo

It really is amazing that Decipher will make such a statement on 38 pts (and I bet far too many then take these recs as gospel). My personal proton hypofractionated only non-ADT UIR database has more men.

Niema Razavian, MD (@radoncdoc_niema) 's Twitter Profile Photo

Mark Storey David Sher C. Jillian Tsai, MD, PhD We looked at this in a meta-analysis: #\size of LN less important than T stage (aka laterality). Highest risk of contra failure is w T3/4 dx. Failure rates similar by N stage Ryan Hughes jamanetwork.com/journals/jaman…

Mark Storey (@protonstorey) 's Twitter Profile Photo

Radcomp is likely qol data. I believe that is timeline. The primary mace data is scheduled for later 2032 release I believe. Won't be surprised to see this negative short term to then flip on primary metric. Something to watch for. Benefit will be in mace data.